Clinical studies for clinical stage III A (N2) non-resected non-small cell lung cancer administered radiation therapy

Forty patients with non-resected non-small cell lung cancer (Clinical Stage III A, N2) administered radiation therapy (RT) were evaluated. All cases were treated by definite radiation dose, over 50gy. In these patients, 17 were treated with RT alone, and 23 with RT and systemic chemotherapy (CT). In RT＋CT group, cis-plutinum (CDDP) was administered for 16 patients. The median survival time of overall patients from initiation of RT was 13 months. Primary response rate was 65%, and survival was higher in response group than non response group (P＜0.05). Among 36 patients with perfprmance status 0 or 1, no significant differences in survival rate were observed among patients with different histological types. However, survival was higher with RT＋CT (with CDDP) than with other therapies (P＜0.05). Therefore, we consider that RT＋CT (with CDDP) is a useful method in this stage.